Blood pressure control with cilnidipine treatment in Japanese post-stroke hypertensive patients: The CA-ATTEND study

Abstract

Blood pressure control is important in post-stroke hypertensive patients and antihypertensive treatment is recommended for such patients. Ca-channel blockers are recommended as the medications of choice for the treatment of post-stroke patients. Here, we report the results of a large-scale prospective postmarketing surveillance study of post-stroke hypertensive patients (n = 2667, male 60.4%, 69.0 ± 10.9 years) treated with cilnidipine, with regard to blood pressure control and adverse reactions. Cilnidipine treatment caused a decrease in both clinic and home blood pressures 2 months after the beginning of treatment, and the decreased blood pressure was maintained until the end of 12 months' observation. The proportion of patients in whom clinic blood pressure was well controlled (<140/90 mmHg) increased from 21.5% to 65.3% in cilnidipine treatment, with no differences in effectiveness among the various clinical subtypes of stroke. In total, 346 adverse events occurred, with an overall incidence of 8.9% (238 of 2667 patients). In the elderly group, specifically, a fall and a hip fracture each occurred in 1 (0.1%) patient. These results indicate that cilnidipine was effective in treating uncontrolled blood pressure and was well tolerated in Japanese post-stroke hypertensive patients in a real-world clinical setting. ARTICLE HISTORY

A post-marketing survey evaluating the safety and efficacy of a fixed-dose single-pill combination of cilnidipine and valsartan in patients with hypertension: Real-world JSH 2014 and 2019 implementations

“…Dizziness and decrease in blood pressure were not serious ADRs and were resolved or resolving in all patients. (between May 2011 and June 2013) (20). We have also reported that the incidence rate of adverse reactions due to coadministration of cilnidipine and ARBs was 2.50% (73 of 2920 patients) (From February 2003 to July 2004) (15), and the incidence rate in the selected 615 patients who were administered 10 mg cilnidipine and 80 mg valsartan was 3.25% (20 of 615 patents) (21).…”

Effects of Cilnidipine, an L/N-Type Calcium Channel Blocker, on Carotid Atherosclerosis in Japanese Post-Stroke Hypertensive Patients: Results from the CA-ATTEND Study

“…The study design, patient characteristics, and main BP results of the CA-ATTEND study have been reported elsewhere 15 ) . This study was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000005523).…”

“…The Carotid Atherosclerosis-Antihypertensive Treatment Trial, Effect of N-type Calcium Channel Blocker for Cerebrovascular Disease (CA-ATTEND) study is a 12-month, large-scale ( n = 2,667), prospective postmarketing surveillance (PMS) study in which the efficacy and safety of cilnidipine were investigated in registered post-stroke hypertensive patients on the basis of pressure (BP) and atherosclerosis of the common carotid arteries 15 ) . Cilnidipine is a dual L/N-Type calcium channel blocker that can block not only L-type vascular calcium channels but also N-type calcium channels in the sympathetic nerves 16 ) .…”

Efficacy of Cilnidipine (L/N-type Calcium Channel Blocker) in Treatment of Hypertension: A Meta-Analysis of Randomized and Non-randomized Controlled Trials

“…In another large-scale prospective post-marketing surveillance study of post-stroke hypertensive patients (n = 2667, male 60.4%, 69.0 ± 10.9 years) who were treated with Cilnidipine, the blood pressure control with Cilnidipine treatment was very good [ 14 ].…”